Krishnan Ramanathan has been named Gates Medical Research Institute’s permanent CEO after more than seven months serving as its interim chief.
Gates MRI is one of the largest players in global health and infectious disease R&D, focusing on medical interventions for diseases that disproportionately affect people in low- and middle-income countries. Ramanathan’s rise to the top of the organization crowns a long track record in global health, immunology and vaccines.
A Big Pharma veteran, Ramanathan spent 15 years working his way up the ranks at Novartis in leadership roles across various therapeutic areas. Most recently, Ramanathan was Johnson & Johnson’s senior vice president and head of portfolio and asset management in immunology.
Gates MRI, an affiliate of the Gates Foundation, has long maintained an R&D focus on malaria and tuberculosis. The organization is advancing eight pipeline candidates, including a late-stage vaccine for TB.
Earlier this year, Gates MRI announced a manufacturing pact with Serum Institute of India to scale capacity for its TB candidate dubbed M72/AS01E. If the shot succeeds in the clinic and wins approval, it would be the first new vaccine for TB in over 100 years.
Gates MRI also licensed out a novel RSV preventive monoclonal antibody candidate to SK Bioscience in a deal earlier this year. SK Bioscience submitted a clinical trial application in South Africa in August to run a phase 1b study testing the mAb’s safety and pharmacokinetics in about 80 infants.
Leveraging Ramanathan’s career in pharma could help as Gates MRI’s clinical hopefuls work their way toward potential approvals, according to Trevor Mundel, president of global health at the Gates Foundation and chair of the Gates MRI board of directors.
“[Ramanathan’s] deep experience in drug and vaccine development, combined with his commitment to partnership, will be invaluable as Gates MRI works to accelerate progress against diseases like tuberculosis,” Mundel said in a statement.